ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > KIR2DL1

KIR2DL1

概要

Name:Killer cell immunoglobulin-like receptor 2DL1
Target Synonym:KIR2DL1,NKAT-1,NKAT1,MHC class I NK cell receptor,Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1,Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 1,P58 Natural Killer Cell Receptor Clones CL-42/47.11,P58 Killer Cell Inhibitory Receptor KIR-K64,Natural Killer-Associated Transcript 1,P58.1 MHC Class-I-Specific NK Receptor,CD158 Antigen-Like Family Member A,P58 NK Receptor CL-42/47.11,CD158A,Killer Cell Immunoglobulin-Like Receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
KI1-H5255 Human Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag
KI1-H5255-structure
KI1-H5255-sds
ACRO Quality

生物活性データの一部

KI1-H5255-ELISA
 KIR2DL1 ELISA

Immobilized Human KIR2DL1, Fc Tag (Cat. No. KI1-H5255) at 1 μg/mL (100 μL/well) can bind Lirilummab with a linear range of 0.1-8 ng/mL (QC tested).

Synonym Name

CD158a

Background

Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Leukemia; Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Hodgkin Disease; Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute Details

This web search service is supported by Google Inc.

totopphone